| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on August 26, 2005
Accepted on December 16, 2005
Department of Clinical Nutrition, German Institute of Human Nutrition Potsdam-Rehbruecke, 14558 Nuthetal, Germany and Department of Endocrinology, Diabetes and Nutrition, Charité-University Medicine Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany
* To whom correspondence should be addressed. E-mail: mmoehlig{at}mail.dife.de.
Context and Objective: Insulin resistance is a central feature of type 2 diabetes. Salicylates prevent lipid-induced insulin resistance in rodents by interrupting inflammatory pathways. We therefore investigated whether salicylates reduce lipid-induced insulin resistance in humans by affecting inflammatory pathways as reflected by serum adipocytokines.
Participants and Intervention: Ten healthy men were included in a cross-over intervention study. Four euglycemic-hyperinsulinemic clamps were performed, one without pretreatment, one with prior 2-hour lipid infusion, one after pretreatment with 4 g acetylsalicylic acid (ASA), and one with ASA pretreatment and prior lipid infusion.
Main Outcome Measure: Lipid-induced insulin resistance was quantified by the euglycemic-hyperinsulinemic clamp technique running at least 2 h. Repeated measurement ANOVA on two factors was used for comparison and results were Bonferroni adjusted for multiple measurements. ASA effects on serum adipocytokines were addressed by comparing the areas under the curves.
Results: Glucose infusion rate (M-value) of the control clamp without pretreatment was 6.3 (± 0.6) mg/kg/min. ASA pretreatment did not change glucose infusion rates (P = 0.6). Lipid infusion significantly decreased the M-value to 4.1 (± 0.6) mg/kg/min (P = 0.008). After ASA pretreatment and lipid infusion the M-value was 4.8 (± 0.7) mg/kg/min and was significantly improved compared with the lipid only clamp (P = 0.036 after Bonferroni's adjustment). General biomarkers of inflammatory processes (IL-6, CRP), the insulin-sensitizing mediator adiponectin, and circulating adiponectin oligomers were unchanged by ASA pretreatment.
Conclusions: ASA pretreatment attenuated lipid-induced insulin resistance in healthy humans. This acute insulin sensitizing effect of ASA was unrelated to changes of circulating inflammatory markers.
This article has been cited by other articles:
 |
|
 |
|
  N. Anderson and J. Borlak Molecular Mechanisms and Therapeutic Targets in Steatosis and Steatohepatitis Pharmacol. Rev., September 1, 2008; 60(3): 311 - 357. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-M. Fernandez-Real, A. Lopez-Bermejo, A.-B. Ropero, S. Piquer, A. Nadal, J. Bassols, R. Casamitjana, R. Gomis, E. Arnaiz, I. Perez, et al. Salicylates Increase Insulin Secretion in Healthy Obese Subjects J. Clin. Endocrinol. Metab., July 1, 2008; 93(7): 2523 - 2530. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Manrique, G. Lastra, J. Palmer, M. Gardner, and J. R. Sowers Review: Aspirin and Diabetes Mellitus: revisiting an old player Therapeutic Advances in Cardiovascular Disease, February 1, 2008; 2(1): 37 - 42. [Abstract] [PDF]
|
|
|
|
|
|
S. N. van der Crabben, G. Allick, M. T. Ackermans, E. Endert, J. A. Romijn, and H. P. Sauerwein Prolonged Fasting Induces Peripheral Insulin Resistance, Which Is Not Ameliorated by High-Dose Salicylate J. Clin. Endocrinol. Metab., February 1, 2008; 93(2): 638 - 641. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Zu, H. Jiang, J. He, C. Xu, S. Pu, M. Liu, and G. Xu Salicylate Blocks Lipolytic Actions of Tumor Necrosis Factor-{alpha} in Primary Rat Adipocytes Mol. Pharmacol., January 1, 2008; 73(1): 215 - 223. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
